预约演示

Biotechs Sesen and Carisma blend together in bid to transform cancer treatment

2022-09-21

细胞疗法并购合作

Carisma’s president and CEO Steven Kelly will lead the combined company once the merger closes.

Carismaio and privately held Carisma Therapeutics are merging, with plans to combine into a “well-funded” biotech that will operate under Carisma’s name and work to advance its engineered macrophages for cancer treatment.

Sesen Bior is set to close inCarisma Therapeuticsour months, at which time the biotech will trade on the Nasdaq under the ticker “CARM,” aCarismag to a Sept. 21 release.cancer

In a financing round concurrent with the merger proposal, Philadelphia-based Carisma has secured $30 million from several investors, including Big Pharmas AbbVie and Merck & Co. The financing is expected to close alongside the merger.

With the cash expected from both companies and the new $30 million, the combiCarismatech will have about $180 million in cash, equivalents and marketable securities—mMerck & Co.s expected to fund the company through 2024.

Sesen, which is focused on targeted fusion protein therapeutics to treat cancer, recently hit the brakes on its phase 3 bladder cancer program after talks with the FDA. The Cambridge, Massachusetts-based biotech paused U.S. clinical development of its most advanced product, Vicineum, to preserve cash.

Sesen transaction represents the result of a thoughtful and careful reviecancertrategic alternatives over the past four bladder cancer which Carisma’s clinical progFDAs, management team and corporate strategy stood out amongst the 42 bids reviewed,” said Thomas Cannell, Sesen’s president and CEO.

The combined company will work to advance Carisma’s cell therapy platform designed to use engineered macrophages and monocytes to treat canceCarismacompany’s chimeric antigen receptor macrophage (CAR-M) platform can be used to fine-tune specific immune cell targets, opening the door for potential therapeutic applications beyond oncology.

Carisma’s lead candidate is a CAR-M cell tCarisma dubbed CT-0508, which is currently being assessed in a phase 1 clinical trial among pacancer with advanced HER2+ solid tumors. Carisma is also working to expand its oncology pipeline both independently and via a recent partnership with Moderna, in which the biotech received $45 million cash for the discovery, development and commercialization of in vivo CAR-M therapies.

Carismaen merger will give Carisma financial strength to CT-0508e to develop CT-0508 and foster additional strong strategic partnerships, said Steveadvanced HER2+ solid tumorst Carisma. Kelly will lead the combined company once the merger closes.Moderna

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构